Gutlix (5ml Each) Oral Suspension contains Bacillus clausii spores at a concentration of 2 billion per dose, serving as a probiotic agent aimed at restoring and maintaining a balanced intestinal microflora. Bacillus clausii is a non-pathogenic, spore-forming bacterium known for its resilience through the gastrointestinal tract, enabling effective colonization and modulation of gut flora. Gutlix is indicated for the prevention and treatment of dysbiosis associated with antibiotic therapy, acute and chronic diarrhea, and other gastrointestinal disturbances such as irritable bowel syndrome and inflammatory bowel conditions. The suspension aids in re-establishing the natural microbial balance, thereby enhancing intestinal barrier function and supporting immune responses. It is suitable for use in both adults and children, including pediatric patients, due to its safety profile and minimal risk of adverse effects. Gutlix is administered orally, with dosage tailored according to clinical requirements and patient age. It is important to follow prescribed dosing schedules to achieve optimal therapeutic outcomes. As a probiotic, Gutlix does not interfere with concurrent antibiotic treatments and may be used adjunctively. Patients with severe immunodeficiency or hypersensitivity to any component should consult a healthcare professional prior to use.